Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A National, Prospective, Non-Interventional Study (NIS) in Patients With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy

Next Previous
X
Search
Trial Profile

A National, Prospective, Non-Interventional Study (NIS) in Patients With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms NORA
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 13 Sep 2022 Results of pooled analysis from WITNESS (NCT03455452) and NORA (NCT02940639) assessing baseline characteristics and to assess overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety in the subgroup of pts with nccRCC, after a minimum follow-up of 14.1 months presented at the 47th European Society for Medical Oncology Congress
    • 13 Sep 2022 Results as a part of the IO-Synthesise RCC, from NCT03455452 and NCT02940639, reporting HRQoL outcomes for patients receiving NIVO for previously treated mRCC , presented at the 47th European Society for Medical Oncology Congress
    • 18 May 2022 Planned End Date changed from 31 Jan 2027 to 15 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top